Answer
It treats specified HER2-positive early or advanced breast cancers in adults who meet the previous-treatment and disease-status requirements of its UK licence.
Sources for this answer
- Kadcyla 100 mg and 160 mg Powder for Concentrate for Solution for Infusion — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.